Dermapharm Holding SE (DMP.DE) Stock

DMP.DE logo

Dermapharm Holding SE

DMP.DEGermany
Healthcare

Company profile

Dermapharm Holding reported revenue of 1.18 billion EUR for fiscal year 2024, up 4.0% from fiscal year 2023, and net income of 113.79 million EUR. That is a net profit margin of 9.6% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 272.15 million EUR, down 2.7% from a year before. Its largest business segment, Branded Pharmaceuticals, brought in 53% of segment revenue in fiscal year 2025; Germany was the largest region with 60%. In Q2 2025 it reported net income of 20.89 million EUR, against net income of 17.27 million EUR a year earlier. Our analysis of its filings shows revenue growing from 1.02 billion EUR in fiscal year 2022 to 1.18 billion EUR in fiscal year 2024, 7.3% a year on average. Dermapharm Holding reports about 3,619 full-time employees.

What stands out

  • Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2024.

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

Largest shareholders

  • Wilhelm Beier88.57 %88.57%
  • Dermapharm Holding Se8.68%
  • Mawer Investment Management Ltd.3.23%
  • Paladin Invest GmbH0.13%
  • Knoesel & Ronge Vermögensverwaltung GmbH & Co. KG0.04%

Share of the company, as of September 25, 2026

Leadership

  • Hans-Georg Feldmeier — CEO & Chairman of the Management Board
  • Christof Dreibholz — CFO, Chief Compliance Officer & Member of Management Board, 57
  • Andreas Eberhorn — Chief Marketing Officer & Member of Management Board, 49
  • Britta Hamberger — Head of Investor Relations & Corporate Communications

How much revenue does Dermapharm Holding make?

Dermapharm Holding reported 1.18 billion EUR in revenue for fiscal year 2024, up 4.0% from 1.14 billion EUR in fiscal year 2023. In Q2 2025 revenue was 272.15 million EUR.

What is Dermapharm Holding's largest business segment?

Branded Pharmaceuticals, with 629.16 million EUR or 53% of segment revenue in fiscal year 2025. Next: Other Healthcare Products (30%) and Parallel Import Business (17%).

Where does Dermapharm Holding make most of its revenue?

Germany: 60% of revenue by region in fiscal year 2025, followed by France (12%).

What companies are similar to Dermapharm Holding?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Merck KGaA (MRK.DE), Bayer Aktiengesellschaft (BAYN.DE), Biotest Aktiengesellschaft (BIO3.DE), Cannovum Cannabis AG (27N0.DE).

How has Dermapharm Holding's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 793.83 million EUR; FY2021, 942.91 million EUR; FY2022, 1.02 billion EUR; FY2023, 1.14 billion EUR; FY2024, 1.18 billion EUR.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees3,619
HeadquartersGrünwald, Germany
ExchangeXETRA
TimezoneEurope/Berlin (CET)

Contact & Links

Address
Lil-Dagover-Ring 7, Grünwald, 82031
Phone
49 89 6 41 86 0
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Dermapharm Holding SE (DMP.DE)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/DMP.DE

LinkedInLinkedInXXYouTubeYouTube